3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Sarcoma
5
Neoplasms
5
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Hepatocellular
2
Advanced Solid Tumors
2
Advanced Cancer
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Non-small Cell Lung Cancer
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
MSI-H or dMMR Advanced Solid Tumors
1
Lung Neoplasms
1
Leiomyosarcoma
1
Gynecological Cancer
1
Gastrointestinal Stromal Tumors
1
Gastroenteropancreatic Neuroendocrine Tumor G3
1
Fallopian Tube Neoplasms
1
Extensive Small Cell Lung Cancer
1
Esophageal Squamous Cell Carcinoma
1
Digestive System Neoplasms
1
Differentiated Thyroid Cancer
1
Interventions
Doxorubicin
5
Dacarbazine
5
Trabectedin
3
belinostat
2
PTC596
2
toripalimab
1
soblidotin
1
rucaparib
1
ridaforolimus
1
reolysin
1
pembrolizumab
1
pazopanib
1
olaratumab
1
futibatinib
1
cixutumumab
1
cemiplimab
1
anlotinib
1
Tablets
1
TTI-621
1
Rosuvastatin Calcium
1
PM 01183
1
Midazolam
1
Injections
1
Imatinib Mesylate
1
Ifosfamide
1
Fluorouracil
1
Erlotinib Hydrochloride
1
Docetaxel
1
Digoxin
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leiomyosarcoma
×
anlotinib
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled